Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
You could win a cash prize of up to £25,000 when you play the JDRF lottery. As well as the chance to win great prizes, you'll also help fund our research to find a cure for type 1 diabetes.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join us on Saturday 21 September 2024 with hundreds of JDRF supporters celebrating One Walk Belfast!
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF is undergoing a transformation.We are becoming Breakthrough T1D in October.
Home > News & events > News > MHRA safety warning for Roche Accu-Chek Insight insulin pump and NovoRapid PumpCart prefilled insulin cartridge
The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a safety warning about the NovoRapid PumpCart prefilled insulin cartridge and the Roche Accu-Chek Insight Insulin pump.
This follows concerns raised about cracked cartridges and insulin leaks.
The MHRA is advising healthcare professionals to contact people who are affected by 26 November 2022.
In the meantime, the agency has provided these recommendations for users of the pump and insulin cartridges:
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a national patient safety alert for the NovoRapid PumpCart prefilled insulin cartridge and the Roche Accu-Chek Insight insulin pump system following concerns raised about cracked cartridges and insulin leaks.
Patients are being asked to check the pre-filled glass insulin cartridge for cracks prior to use. The cartridge should not be used if it has been dropped even if no cracks are visible. Closely follow the updated handling instructions in the pump user manual when changing pre-filled glass insulin cartridges.
The device, which releases the insulin your body needs throughout the day and night, comprises a pump, tube, battery and a pre-filled glass insulin cartridge. In some of the reported leakage incidents, the cartridges were found to be cracked and provided an inadequate supply of insulin to patients. However, leakages also occurred in cases where no cracks in the cartridge were visible. In some patients, there were consequences of not receiving enough insulin from their pump system, including reports of severely high blood sugar and diabetic ketoacidosis (a serious complication of diabetes when the body produces high levels of blood acids called ketones).
Healthcare professionals are being advised to contact patients over the next six months using said device to discuss their individual needs and source an alternative pump where appropriate.
Key patient recommendations are:
Dr June Raine, Chief Executive, Medicines and Healthcare products Regulatory Agency said: “For many patients with diabetes, insulin pumps are an important method of treatment and provide freedom and flexibility in the day to day management of their condition. Because of the rare risk of insulin leakage from the Roche Accu-Chek Insight insulin pump, patients should check the pre-filled glass insulin cartridge for any cracks prior to usage.
“We would like to reassure patients that the risk of leakage remains low when used in accordance with instructions and today’s safety recommendations. Patients should continue to use their insulin pump as recommended whilst they await contact from their healthcare professional regarding an alternative device.
“If you suspect a problem with your insulin pump, please seek medical advice immediately.”
Professor Partha Kar, National Specialty Advisor, Diabetes with NHS England and co-lead of Diabetes GIRFT with NHS Improvement said: “We are grateful to the MHRA for working closely with us on the issue of insulin pumps and any relevant safety concerns. We would encourage healthcare professionals to carefully review the National Patient Safety Alert and discuss with relevant patients the risks and appropriate mitigations as needed. We would remind patients that they should not change treatment methods without first consulting a relevant healthcare professional.”
Read the National Patient Safety Alert and advice for healthcare professionals here.
In an historic advancement in the treatment of type 1 diabetes, the National Institute for Health and Care Excellence (NICE) today approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales.
As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.
Insulet, the company who make Omnipod® products, has announced that their Omnipod® 5 hybrid closed loop (HCL) technology is now available in the UK.